Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504422 | 0.86 | MMP8 (0.43) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL1682735 | 0.86 | CYP4F2 (0.41) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL8599101 | 0.85 | PKM (0.39) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL688771 | 0.83 | ALOX15 (0.39) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL13936374 | 0.83 | ALDH1A1 (0.37) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL11378341 | 0.83 | MMP8 (0.41) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL25981521 | 0.83 | HCAR2 (0.35) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL29088565 | 0.82 | MMP8 (0.38) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL13539346 | 0.81 | MMP8 (0.36) | MMP8ALDH1A1LMNAHSD17B10PKM | |
| SCHEMBL17898134 | 0.81 | MMP8 (0.40) | MMP8ALDH1A1LMNAHSD17B10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122025824-A | Electrolyte, secondary battery, and electricity-using device | 蜂巢能源科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-119833729-A | Gel electrolyte of low-temperature lithium ion battery, and preparation method and application thereof | 香河昆仑新能源材料股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118248950-A | Local high-concentration electrolyte, preparation method thereof and lithium metal battery | 电子科技大学 | 2024-06-25 | — | — | CN | claimed |
| CN-117039172-A | Lithium fluorocarboxylate sodium salt electrolyte | 广东佳信新材料科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-122073257-A | Sodium ion battery electrolyte and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2026-05-22 | — | — | CN | disclosed |
| CN-122025824-A | Electrolyte, secondary battery, and electricity-using device | 蜂巢能源科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-120077502-A | Electrolyte, electrochemical device, secondary battery, and lithium ion secondary battery | 大金工业株式会社 | 2025-05-30 | — | — | CN | disclosed |
| CN-119833729-A | Gel electrolyte of low-temperature lithium ion battery, and preparation method and application thereof | 香河昆仑新能源材料股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119422259-A | Surface treatment agent for electrode material, positive electrode active material, current collecting foil, negative electrode active material, conductive auxiliary agent, electrode, battery, method for producing positive electrode active material, method for producing current collecting foil, method for producing negative electrode active material, method for producing conductive auxiliary agent, and method for producing electrode | 大金工业株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-119318048-A | Electrolyte and secondary battery using the same | 大金工业株式会社 | 2025-01-14 | — | — | CN | disclosed |
| CN-118248950-A | Local high-concentration electrolyte, preparation method thereof and lithium metal battery | 电子科技大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-117039172-A | Lithium fluorocarboxylate sodium salt electrolyte | 广东佳信新材料科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | TBD | 2007-02-15 | — | — | US | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2007008563-A2 | PREPARATION OF PEGYLATED CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006127584-A1 | IMIDAZOLONE PHENYLALANINE DERIVATIVES AS VLA-4 ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006010054-A2 | MULTIVALENT VLA-4 ANTAGONISTS COMPRISING POLYETHYLENE GLYCOL MOIETIES | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060013799-A1 | Multimeric VLA-4 antagonists comprising polymer moieties | ELAN PHARMACEUTICAL INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005111020-A2 | PYRIMIDINE HYDANTOIN ANALOGUES WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | VCAM1, ICAM1, IL4I1 | MMP8 4047/4885ALDH1A1 641/4885LMNA 2422/4885 |
| US-20060013799-A1 | Multimeric VLA-4 antagonists comprising polymer moieties | VCAM1, ICAM1, ITGB4 | MMP8 1083/4885ALDH1A1 748/4885LMNA 3506/4885 |
| US-20050261324-A1 | Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, LPAR4 | MMP8 852/4885ALDH1A1 280/4885LMNA 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.